# US 2021/0330597 A1 · Nanoparticle Depot For Controlled And Sustained Gene Delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330597 A1
- Document ID: US20210330597A1
- Status: Published application
- Kind: A1
- Application number: 17/240,405
- Filed: 2021-04-26
- Published: 2021-10-28
- Earliest claimed: 2020-04-27
- Assignees: New Jersey Institute of Technology
- Applicants: New Jersey Institute of Technology
- Inventors: Xiaoyang Xu; Zhongyu Li; William Ho
- Web page: https://patentgrep.com/patent/US20210330597A1

## CPC

- A61K 9/5115: {Inorganic compounds}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 48/0041: {the non-active part being polymeric}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

One aspect of the disclosure describes a lipid conjugated cationic molecule. Other aspects of the disclosure describes nanoparticle delivery systems and methods of making the systems are disclosed. An embodiment of the nanoparticle delivery system has sustained gene delivery properties, the nanoparticle delivery system can be synthesized using biodegradable and biocompatible polymers via self-assembly. The nanoparticle delivery system comprises a plurality of nanoparticle depots, each of which has a particle-in-particle structure, and is composed of a polymeric nanoparticle, which encapsulates cationic molecule/nucleic acid complexes, facilitating enhanced retention and prolonged release of the gene payload. The polymeric nanoparticle comprises a shell, and a nanocomplex of the cationic molecule and a polynucleotide, the nanocomplexes are distributed within the shell and/or embedded in the shell. Another embodiment of the nanoparticle delivery system has one or more nanocomplexes. The one or more nanocomplexes includes a lipid conjugated cationic molecule and a polynucleotide.

## Claims

### Claim 1

A nanoparticle delivery system comprising a plurality of nanoparticle depots, each of the nanoparticle depots comprising:
a polymeric nanoparticle comprising a shell encapsulating a core; and
one or more nanocomplexes within the polymeric nanoparticle, the nanocomplex comprising a cationic molecule and a polynucleotide.

### Claim 2 (depends on 1)

The nanoparticle delivery system of claim 1 that is effective for sustained release of the polynucleotide.

### Claim 3 (depends on 1)

The nanoparticle delivery system of claim 1, wherein the cationic molecule comprises: a poly (β-amino ester) (PBAE), a poly (ethylenimine) (pEI), a poly (2-dimethylaminoethyl methacrylate) (pDMAEMA), a poly-L-lysine (pLL), or derivatives, or conjugates thereof.

### Claim 4 (depends on 3)

The nanoparticle delivery system of claim 3, wherein the cationic molecule comprises a lipid conjugated cationic molecule.

### Claim 5 (depends on 4)

The nanoparticle delivery system of claim 4, wherein the lipid conjugated cationic molecule comprises a lipid conjugated poly (β-amino ester) (L-PBAE).

### Claim 6 (depends on 1)

The nanoparticle delivery system of claim 1, wherein the cationic molecule comprises a lipid grafted co-polymer of: a poly (β-amino ester) (PBAE) and one or more lipid acids, the one or more lipid acids comprising: methanoic acid (C1), ethanoic acid (C2), propanoic acid (C3), butanoic acid (C4), pentanoic acid (C5), hexanoic acid (C6), heptanoic acid (C7), octanoic acid (C8), nonanoic acid (C9), decanoic acid (C10), undecanoic acid (C11), dodecanoic acid (C12), tridecanoic acid (C13), tetradecanoic acid (C14), pentadecanoic acid (C15), hexadecanoic acid (C16), heptadecanoic acid (C17), octadecanoic acid (C18), oleic acid, linoleic acid, nonadecanoic acid (C19), eicosanoic acid (C20), heneicosanoic acid (C21), docosanoic acid (C22), tricosanoic acid (C23), tetracosanoic acid (C24), pentacosanoic acid (C25), hexacosanoic acid (C26), and their derivatives, or combination thereof.

### Claim 7 (depends on 1)

The nanoparticle delivery system of claim 1, wherein the polynucleotide comprises a cDNA, an siRNA, a microRNA, an mRNA, a plasmid, or their antisense, single-stranded, double-stranded, or circular varieties.

### Claim 8 (depends on 1)

The nanoparticle delivery system of claim 1, wherein the polymeric nanoparticle has a mean particle size in a range of from 50 nm to 500 nm.

### Claim 9 (depends on 1)

The nanoparticle delivery system of claim 1, wherein the polymeric nanoparticle comprises a biodegradable amphiphilic material comprising a poly(lactic acid) (PLA), a poly(glycolic acid) (PGA), a poly(D,L-lactic-co-glycolic acid) (PLGA), or combinations thereof.

### Claim 10 (depends on 1)

The nanoparticle delivery system of claim 1, wherein the shell comprises a poly(D,L-lactic-co-glycolic acid) (PLGA) and an outer surface of the polymeric protective nanoparticle comprises a poly(ethylene glycol) (PEG).

### Claim 11 (depends on 1)

The nanoparticle delivery system of claim 1, wherein the polymeric nanoparticle has a zeta potential in a range of from −40 mV to +80 mV.

### Claim 12 (depends on 2)

The nanoparticle delivery system of claim 2 effective to release 80% of the polynucleotide in a range of from 3 to 10 days as measured by a PicoGreen assay.

### Claim 13

A nanoparticle delivery system comprising a plurality of nanoparticle depots, each of the nanoparticle depots comprising:
a polymeric nanoparticle comprising a shell encapsulating a core, the polymeric nanoparticle comprising a poly (D,L-lactic-co-glycolic acid) (PLGA)-polyethylene glycol (PEG) block co-polymer, wherein the shell comprises the PLGA and an outer surface of the polymeric protective nanoparticle comprises the PEG, the polymeric nanoparticle having a mean particle size in a range of from 50 nm to 500 nm; and
one or more nanocomplexes located in the core of the polymeric nanoparticle, the nanocomplex comprises a cationic molecule and a polynucleotide, the cationic molecule comprises a poly (β-amino ester) (PBAE), a poly (ethylenimine) (pEI), a poly (2-dimethylaminoethyl methacrylate) (pDMAEMA), a poly-L-lysine (pLL), or co-polymers, derivatives, or conjugates thereof, the nanocomplex having a mean particle size in a range of from 5 nm to 80 nm.

### Claim 14 (depends on 13)

The nanoparticle delivery system of claim 13, wherein the cationic molecule comprises a lipid-conjugated PBAE (L-PBAE).

### Claim 15

A lipid conjugated cationic molecule comprising:
a cationic molecule comprising a poly (β-amino ester) (PBAE), a poly (ethylenimine) (pEI), a poly (2-dimethylaminoethyl methacrylate) (pDMAEMA), a poly-L-lysine (pLL), or derivatives, or conjugates thereof; and
one or more lipid acids, the one or more lipid acids comprising methanoic acid (C1), ethanoic acid (C2), propanoic acid (C3), butanoic acid (C4), pentanoic acid (C5), hexanoic acid (C6), heptanoic acid (C7), octanoic acid (C8), nonanoic acid (C9), decanoic acid (C10), undecanoic acid (C11), dodecanoic acid (C12), tridecanoic acid (C13), tetradecanoic acid (C14), pentadecanoic acid (C15), hexadecanoic acid (C16), heptadecanoic acid (C17), octadecanoic acid (C18), oleic acid, linoleic acid, nonadecanoic acid (C19), eicosanoic acid (C20), heneicosanoic acid (C21), docosanoic acid (C22), tricosanoic acid (C23), tetracosanoic acid (C24), pentacosanoic acid (C25), hexacosanoic acid (C26), and their derivatives, or combination thereof.

### Claim 16 (depends on 15)

The lipid conjugated cationic molecule of claim 15 comprising a molecular weight in a range of from 1200 Daltons to 40000 Daltons.

### Claim 17 (depends on 15)

The lipid conjugated cationic molecule of claim 15 comprising a weight ratio of lipid:cationic molecule in a range of from 1:100 to 1:1.

### Claim 18 (depends on 15)

A nanoparticle delivery system comprising one or more nanocomplexes, the nanocomplex comprises the lipid conjugated cationic molecule of claim 15 and a polynucleotide.

### Claim 19 (depends on 18)

The nanoparticle delivery system of claim 18, wherein the polynucleotide comprises a cDNA, an siRNA, a microRNA, an mRNA, a plasmid, or their antisense, single-stranded, double-stranded, or circular varieties.

### Claim 20 (depends on 18)

The nanoparticle delivery system of claim 18, wherein the one or more nanocomplexes comprises a mean particle size in a range of from 5 nm to 80 nm.
